UnitedHealth's premium valuation of 25.6x earnings faces scrutiny as commercial margin recovery stalls and revenue growth lags behind Cigna and CVS.
UnitedHealth trades at a premium valuation despite slowest revenue growth and delayed commercial margin recovery, suggesting downside risk.
Cigna is highlighted as a peer with lower valuation, faster revenue growth, and stronger relative value compared to UNH.
CVS is mentioned with high trailing return but distorted earnings due to a loss quarter, making comparison less clean.
UnitedHealth Group faces valuation headwinds as it trades at a significant premium to peers like Cigna despite recording the slowest revenue growth among the trio. While the company maintains a strong operating margin lead through its Optum services, commercial margin recovery remains delayed beyond 2027 due to rising medical cost trends and regulatory pressures.
UnitedHealth trades at a premium valuation of 25.6x trailing earnings, which is significantly higher than Cigna's 11.3x, despite UnitedHealth reporting the slowest revenue growth in the peer group.
Commercial margins are pressured by medical cost trends running above 11% and incremental costs stemming from the No Surprises Act arbitration process.